Does xgeva cause onj?

What is the Risk of Onychoonychomycosis (ONJ) with Xgeva?

Xgeva (denosumab) is a medication used to treat bone metastases and increase bone mass in patients with cancer-related conditions. However, it has been linked to a rare but serious side effect called onychoonychomycosis (ONJ), also known as bisphosphonate-induced ONJ.

[1] According to the FDA, ONJ is characterized by the destruction of the jawbone and is often associated with prolonged bisphosphonate use. Research suggests that denosumab may increase the risk of ONJ, particularly in patients with a history of dental surgery, poor oral health, or those taking other medications that affect bone metabolism.

Studies have estimated the risk of developing ONJ while taking Xgeva to be around 1 in 10,000 to 1 in 50,000 patients. However, the exact risk is difficult to determine due to limited data and varying definitions of ONJ.

[2] The American Dental Association (ADA) advises patients to maintain good oral hygiene and schedule regular dental check-ups while taking Xgeva or other bisphosphonate medications to mitigate the risk of ONJ.

How Does Xgeva Impact Dental Health?

Research has shown that Xgeva can impact dental health in several ways:

[3] * Reduced salivary flow: Xgeva can decrease saliva production, making patients more susceptible to oral infections and dental problems.
* Impaired healing: Bisphosphonates like denosumab can disrupt the healing process, leading to delayed or incomplete recovery of dental soft and hard tissues.

Patient-Specific Risks

Certain factors may increase an individual's risk of developing ONJ while taking Xgeva, including:

* History of dental surgery or procedures
* Poor oral health, such as untreated teeth or gum disease
* Use of other medications that affect bone metabolism
* Prolonged duration of bisphosphonate therapy

Prevention and Management

To minimize the risk of ONJ, patients taking Xgeva should:

* Regularly visit a dentist for check-ups and cleanings
* Maintain good oral hygiene habits
* Avoid dental procedures whenever possible
* Consider alternative treatments for dental conditions

For patients at higher risk, it's essential to discuss the potential benefits and risks of Xgeva with their healthcare provider and consider alternative options.

Citations:

[1] US FDA. (2023). Xgeva (denosumab) Prescribing Information.
[2] American Dental Association. (n.d.). Dentures & Osteoporosis.
[3] National Institutes of Health. (2022). Bisphosphonates and Dental Health.

DrugPatentWatch.com: https://www.drugpatentwatch.com/drug/xgeva/denosumab